| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Risa Sakai, Yoshifumi Irie, Takeshi Murata, Atsushi Ishige, Naoko Anjiki, Kenji Watanab. Toki-to protects dopaminergic neurons in the substantia nigra from neurotoxicity of MPTP in mice. Phytotherapy research : PTR. vol 21. issue 9. 2007-10-29. PMID:17486689. |
parkinson's disease (pd) is a neurodegenerative disease of the brain characterized by the progressive loss of dopaminergic neurons in the substantia nigra (sn). |
2007-10-29 |
2023-08-12 |
mouse |
| Zhenquan Jia, Hara P Misr. Exposure to mixtures of endosulfan and zineb induces apoptotic and necrotic cell death in SH-SY5Y neuroblastoma cells, in vitro. Journal of applied toxicology : JAT. vol 27. issue 5. 2007-10-25. PMID:17309119. |
these findings suggest that the cytotoxicity of endosulfan and zineb, both individually and in mixtures, is associated with the occurrence of early and late apoptotic/necrotic processes in sh-sy5y human neuroblastoma cells and support the contention that pesticide-induced neuronal cell death leading to neurodegenerative disease may, at least in part, be associated with early and late apoptosis of dopaminergic neurons. |
2007-10-25 |
2023-08-12 |
human |
| Enrico Schmidt, Mark Seifert, Ralf Baumeiste. Caenorhabditis elegans as a model system for Parkinson's disease. Neuro-degenerative diseases. vol 4. issue 2-3. 2007-10-12. PMID:17596715. |
parkinson's disease (pd) is one of the most common age-related neurodegenerative diseases that is characterized by selective loss of dopaminergic neurons. |
2007-10-12 |
2023-08-12 |
caenorhabditis_elegans |
| Vittorio Calabrese, Cesare Mancuso, Agrippino Ravagna, Marzia Perluigi, Chiara Cini, Carlo De Marco, D Allan Butterfield, Anna Maria Giuffrida Stell. In vivo induction of heat shock proteins in the substantia nigra following L-DOPA administration is associated with increased activity of mitochondrial complex I and nitrosative stress in rats: regulation by glutathione redox state. Journal of neurochemistry. vol 101. issue 3. 2007-07-18. PMID:17241115. |
parkinson's disease (pd) is a neurodegenerative disease characterized by a severe depletion in number of dopaminergic cells of the substantia nigra (sn). |
2007-07-18 |
2023-08-12 |
rat |
| Ennio Esposito, Vincenzo Di Matteo, Arcangelo Benigno, Massimo Pierucci, Giuseppe Crescimanno, Giuseppe Di Giovann. Non-steroidal anti-inflammatory drugs in Parkinson's disease. Experimental neurology. vol 205. issue 2. 2007-07-10. PMID:17433296. |
parkinson's disease (pd) is known to be a chronic and progressive neurodegenerative disease caused by a selective degeneration of dopaminergic (daergic) neurons in the substantia nigra pars compacta (snc). |
2007-07-10 |
2023-08-12 |
Not clear |
| Dianne McFarlan. Advantages and limitations of the equine disease, pituitary pars intermedia dysfunction as a model of spontaneous dopaminergic neurodegenerative disease. Ageing research reviews. vol 6. issue 1. 2007-06-21. PMID:17374512. |
advantages and limitations of the equine disease, pituitary pars intermedia dysfunction as a model of spontaneous dopaminergic neurodegenerative disease. |
2007-06-21 |
2023-08-12 |
human |
| Hua-Qin Wang, Ryosuke Takahash. Expanding insights on the involvement of endoplasmic reticulum stress in Parkinson's disease. Antioxidants & redox signaling. vol 9. issue 5. 2007-06-04. PMID:17465880. |
parkinson's disease (pd) is the second most common neurodegenerative disease characterized by selective loss of dopaminergic neurons and the presence of lewy bodies. |
2007-06-04 |
2023-08-12 |
Not clear |
| E Ch Wolter. PD-related psychosis: pathophysiology with therapeutical strategies. Journal of neural transmission. Supplementum. issue 71. 2007-05-17. PMID:17447413. |
parkinson's disease (pd) is a chronic, neurodegenerative disease with degeneration of the central dopaminergic neurons in the substantia nigra, leading to a depletion of dopamine (da) in the striatum. |
2007-05-17 |
2023-08-12 |
Not clear |
| Annette E Fleckenstein, Trent J Volz, Evan L Riddle, James W Gibb, Glen R Hanso. New insights into the mechanism of action of amphetamines. Annual review of pharmacology and toxicology. vol 47. 2007-04-10. PMID:17209801. |
all of these mechanisms have potential implications for both amphetamine- and methamphetamine-induced neurotoxicity, as well as dopaminergic neurodegenerative diseases. |
2007-04-10 |
2023-08-12 |
Not clear |
| Marten P Smidt, J Peter H Burbac. How to make a mesodiencephalic dopaminergic neuron. Nature reviews. Neuroscience. vol 8. issue 1. 2007-03-06. PMID:17180160. |
dopaminergic neurons located in the ventral mesodiencephalon are essential for the control of voluntary movement and the regulation of emotion, and are severely affected in neurodegenerative diseases such as parkinson's disease. |
2007-03-06 |
2023-08-12 |
mouse |
| F J Fernandez-Gomez, M D Pastor, E M Garcia-Martinez, R Melero-Fernandez de Mera, M Gou-Fabregas, M Gomez-Lazaro, S Calvo, R M Soler, M F Galindo, J Jordá. Pyruvate protects cerebellar granular cells from 6-hydroxydopamine-induced cytotoxicity by activating the Akt signaling pathway and increasing glutathione peroxidase expression. Neurobiology of disease. vol 24. issue 2. 2007-01-23. PMID:16978869. |
parkinson disease (pd) is the second-most common age-related neurodegenerative disease and is characterized by the selective destruction of dopaminergic neurons. |
2007-01-23 |
2023-08-12 |
rat |
| Shin-ichiro Kubo, Nobutaka Hattori, Yoshikuni Mizun. Recessive Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. vol 21. issue 7. 2006-12-15. PMID:16615060. |
parkinson's disease (pd) is a progressive neurodegenerative disease caused by loss of dopaminergic neurons in the substantia nigra pars compacta. |
2006-12-15 |
2023-08-12 |
Not clear |
| Lorenzo Priano, Maria Rosa Gasco, Alessandro Maur. Transdermal treatment options for neurological disorders: impact on the elderly. Drugs & aging. vol 23. issue 5. 2006-12-05. PMID:16823990. |
moreover, transdermal dopaminergic drugs, particularly rotigotine, seem the ideal treatment for patients experiencing restless legs syndrome or periodic limb movement disorder during sleep, disorders that are quite common in elderly people or in association with neurodegenerative diseases. |
2006-12-05 |
2023-08-12 |
Not clear |
| Ikuko Mizuta, Wataru Satake, Yuko Nakabayashi, Chiyomi Ito, Satoko Suzuki, Yoshio Momose, Yoshitaka Nagai, Akira Oka, Hidetoshi Inoko, Jiro Fukae, Yuko Saito, Motoji Sawabe, Shigeo Murayama, Mitsutoshi Yamamoto, Nobutaka Hattori, Miho Murata, Tatsushi Tod. Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease. Human molecular genetics. vol 15. issue 7. 2006-09-19. PMID:16500997. |
parkinson's disease (pd), one of the most common human neurodegenerative diseases, is characterized by the loss of dopaminergic neurons in the substantia nigra of the midbrain. |
2006-09-19 |
2023-08-12 |
human |
| Seung U Kim, In H Park, Tae H Kim, Kwang S Kim, Hyun B Choi, Seok H Hong, Jung H Bang, Myung A Lee, In S Joo, Chong S Lee, Yong S Ki. Brain transplantation of human neural stem cells transduced with tyrosine hydroxylase and GTP cyclohydrolase 1 provides functional improvement in animal models of Parkinson disease. Neuropathology : official journal of the Japanese Society of Neuropathology. vol 26. issue 2. 2006-06-23. PMID:16708545. |
parkinson disease is a neurodegenerative disease characterized by loss of midbrain dopaminergic neurons resulting in movement disorder. |
2006-06-23 |
2023-08-12 |
human |
| Hitoshi Fukuda, Jun Takahash. Embryonic stem cells as a cell source for treating Parkinson's disease. Expert opinion on biological therapy. vol 5. issue 10. 2006-05-31. PMID:16197334. |
parkinson's disease (pd) is a neurodegenerative disease characterised by a loss of midbrain dopaminergic (da) neurons. |
2006-05-31 |
2023-08-12 |
Not clear |
| Mohamed A Elwan, Jason R Richardson, Thomas S Guillot, W Michael Caudle, Gary W Mille. Pyrethroid pesticide-induced alterations in dopamine transporter function. Toxicology and applied pharmacology. vol 211. issue 3. 2006-04-20. PMID:16005927. |
parkinson's disease (pd) is a progressive neurodegenerative disease affecting the nigrostriatal dopaminergic pathway. |
2006-04-20 |
2023-08-12 |
mouse |
| H Reichman. [Medication treatment for Parkinson's disease]. Der Nervenarzt. vol 76. issue 12. 2006-02-28. PMID:16283151. |
although parkinsonism is an insidious disease of unknown cause resulting in destruction of important dopaminergic neurons, no other neurodegenerative disease can be treated as successfully. |
2006-02-28 |
2023-08-12 |
Not clear |
| J Seibyl, D Jennings, R Tabamo, K Mare. The role of neuroimaging in the early diagnosis and evaluation of Parkinson's disease. Minerva medica. vol 96. issue 5. 2005-12-28. PMID:16227950. |
nonetheless, current unresolved issues around the clinical role of neuroimaging in monitoring patients over time and validation of quantitative imaging measures of dopaminergic function are immediate issues for the field and the subject of current research efforts and the extension of the lessons learned in parkinson's to other neurodegenerative diseases including alzheimer's dementia. |
2005-12-28 |
2023-08-12 |
human |
| Stacy S Wu, Steven J Fruch. Treatment of Parkinson's disease : what's on the horizon? CNS drugs. vol 19. issue 9. 2005-11-07. PMID:16142989. |
although great strides have been made in the development of agents to treat this neurodegenerative disease, none yet address the underlying problem associated with it, the progressive loss of dopaminergic neurons. |
2005-11-07 |
2023-08-12 |
Not clear |